Dp Vii Associates Lp - Net Worth and Insider Trading

Dp Vii Associates Lp Net Worth

The estimated net worth of Dp Vii Associates Lp is at least $455,579 dollars as of 2024-11-13. Dp Vii Associates Lp is the 10% Owner of Zogenix Inc and owns about 13,819 shares of Zogenix Inc (ZGNX) stock worth over $368,691. Dp Vii Associates Lp is the 10% Owner of Esperion Therapeutics Inc and owns about 35,253 shares of Esperion Therapeutics Inc (ESPR) stock worth over $85,841. Dp Vii Associates Lp is also the 10% Owner of Clovis Oncology Inc and owns about 44,034 shares of Clovis Oncology Inc (CLVSQ) stock worth over $661. Besides these, Dp Vii Associates Lp also holds Evoke Pharma Inc (EVOK) , Orexigen Therapeutics Inc (OREXQ) . Details can be seen in Dp Vii Associates Lp's Latest Holdings Summary section.

Disclaimer: The insider information is derived from SEC filings. The estimated net worth is based on the final shares held after open market or private purchases and sales of common stock with a transaction code of "P" or "S" on Form 4, assuming that Dp Vii Associates Lp has not made any transactions after 2016-05-26 and currently still holds the listed stock(s). Please note that this estimate may not reflect the actual net worth.

GuruFocus Premium Membership
30 Years of Financial Data on One Screen
Unlimited Filters in All-in-One Stock Screener
Exclusive Earnings Calls & Stock Analysis
Customizable Stock Dashboard
Real-Time Insider Trading Alerts
8,000+ Institutional Investors’ 13F Holdings
Excel & Google Sheets Integration
Downloadable Data
Quick Customer Support
And Much More...

Transaction Summary of Dp Vii Associates Lp

To

Dp Vii Associates Lp Insider Ownership Reports

Based on ownership reports from SEC filings, as the reporting owner, Dp Vii Associates Lp owns 11 companies in total, including Regado Biosciences Inc (RGDO) , Obalon Therapeutics Inc (OBLN) , and Evoke Pharma Inc (EVOK) among others .

Click here to see the complete history of Dp Vii Associates Lp’s form 4 insider trades.

Insider Ownership Summary of Dp Vii Associates Lp

Ticker Comapny Transaction Date Type of Owner
RGDO Regado Biosciences Inc 2016-11-01 10 percent owner
OBLN Obalon Therapeutics Inc 2016-10-12 10 percent owner
EVOK Evoke Pharma Inc 2016-05-26 10 percent owner
LIMIT LIMIT 2014-11-19 10 percent owner
LIMIT LIMIT 2014-03-17 10 percent owner
LIMIT LIMIT 2013-11-13 10 percent owner
LIMIT LIMIT 2013-07-01 10 percent owner
LIMIT LIMIT 2013-06-04 10 percent owner
LIMIT LIMIT 2011-12-22 10 percent owner
LIMIT LIMIT 2011-09-16 10 percent owner
LIMIT LIMIT 2016-10-05 10 percent owner

Dp Vii Associates Lp Latest Holdings Summary

Dp Vii Associates Lp currently owns a total of 5 stocks. Among these stocks, Dp Vii Associates Lp owns 13,819 shares of Zogenix Inc (ZGNX) as of November 29, 2010, with a value of $368,691 and a weighting of 80.93%. Dp Vii Associates Lp owns 35,253 shares of Esperion Therapeutics Inc (ESPR) as of July 1, 2013, with a value of $85,841 and a weighting of 18.84%. Dp Vii Associates Lp also owns 44,034 shares of Clovis Oncology Inc (CLVSQ) as of June 4, 2013, with a value of $661 and a weighting of 0.14%. The other 2 stocks Evoke Pharma Inc (EVOK) , Orexigen Therapeutics Inc (OREXQ) have a combined weighting of 0.08% among all his current holdings.

Latest Holdings of Dp Vii Associates Lp

Ticker Comapny Latest Transaction Date Shares Owned Current Price ($) Current Value ($)
ZGNX Zogenix Inc 2010-11-29 13,819 26.68 368,691
ESPR Esperion Therapeutics Inc 2013-07-01 35,253 2.44 85,841
CLVSQ Clovis Oncology Inc 2013-06-04 44,034 0.02 661
EVOK Evoke Pharma Inc 2016-05-26 72 5.00 360
OREXQ Orexigen Therapeutics Inc 2011-12-22 5,064 0.01 27

Holding Weightings of Dp Vii Associates Lp


Dp Vii Associates Lp Form 4 Trading Tracker

According to the SEC Form 4 filings, Dp Vii Associates Lp has made a total of 0 transactions in Zogenix Inc (ZGNX) over the past 5 years. The most-recent trade in Zogenix Inc is the acquisition of 4,926 shares on November 29, 2010, which cost Dp Vii Associates Lp around $157,640.

According to the SEC Form 4 filings, Dp Vii Associates Lp has made a total of 0 transactions in Esperion Therapeutics Inc (ESPR) over the past 5 years. The most-recent trade in Esperion Therapeutics Inc is the acquisition of 4,791 shares on July 1, 2013, which cost Dp Vii Associates Lp around $67,074.

According to the SEC Form 4 filings, Dp Vii Associates Lp has made a total of 0 transactions in Clovis Oncology Inc (CLVSQ) over the past 5 years. The most-recent trade in Clovis Oncology Inc is the sale of 2,779 shares on June 4, 2013, which brought Dp Vii Associates Lp around $179,468.

More details on Dp Vii Associates Lp's insider transactions can be found in the Insider Trading History of Dp Vii Associates Lp table.

Insider Trading History of Dp Vii Associates Lp

No transactions are available. GuruFocus only tracks and displays the purchase and sale of non-derivative security in open market or private transactions from SEC filings with the transaction code of P or S.
Total 0
  • 1
Only the transactions in Open Market or Private Sale at the market prices are included. Other transactions such as conversion of derivative security or exercise of options are not included. Insiders are limited to only officers and/or directors of the company.

Dp Vii Associates Lp Trading Performance

GuruFocus tracks the stock performance after each of Dp Vii Associates Lp's buying transactions within different timeframes. To be detailed, the average return of stocks after 3 months bought by Dp Vii Associates Lp is 12.2%. GuruFocus also compares Dp Vii Associates Lp's trading performance to market benchmark return within the same time period. The performance of stocks bought by Dp Vii Associates Lp within 3 months outperforms 3 times out of 17 transactions in total compared to the return of S&P 500 within the same period.

You can select different timeframes to see how Dp Vii Associates Lp's insider trading performs compared to the benchmark.

Please note GuruFocus will not track the insiders’ transaction performance if he/she does not have buying transactions.

Performance of Dp Vii Associates Lp

Average Return

LIMIT
Average return per transaction

Outperforming Transactions

LIMIT
4 out of 17 outperforming transactions.
Each transaction is measured over a period and compared to .
1 Month 3 Months 6 Months 1 Year 2 Years 3 Years
Return(%) 14.3 LIMIT LIMIT LIMIT LIMIT LIMIT
Relative Return to S&P 500(%) 10.2 LIMIT LIMIT LIMIT LIMIT LIMIT

Dp Vii Associates Lp Ownership Network

Ownership Network List of Dp Vii Associates Lp

No Data

Ownership Network Relation of Dp Vii Associates Lp

Insider Network Chart

Dp Vii Associates Lp Owned Company Details

What does Regado Biosciences Inc do?

Who are the key executives at Regado Biosciences Inc?

Dp Vii Associates Lp is the 10 percent owner of Regado Biosciences Inc. Other key executives at Regado Biosciences Inc include 10 percent owner Domain Partners Vi, L.p. , Chief Medical Officer Eric Lefebvre , and Chief Financial Officer Christopher Peetz .

Regado Biosciences Inc (RGDO) Insider Trades Summary

In summary, during the past 3 months, insiders sold 0 shares of Regado Biosciences Inc (RGDO) in total and bought 0 shares, with a net sale of 0 shares. During the past 18 months, 0 shares of Regado Biosciences Inc (RGDO) were sold and 0 shares were bought by its insiders, resulting in a net sale of 0 shares.

Regado Biosciences Inc (RGDO)'s detailed insider trading history can be found in Insider Trading Tracker table.

To

Regado Biosciences Inc Insider Transactions

No Available Data

Dp Vii Associates Lp Mailing Address

Above is the net worth, insider trading, and ownership report for Dp Vii Associates Lp. You might contact Dp Vii Associates Lp via mailing address: One Palmer Sq, Ste 515, Princeton Nj 08542.